INTRODUCTION AGING
Among the immune cells recruited to the tumor site, tumor associated macrophages (TAMs) are key determinants of intra-tumor immune status and modulate as well cancer cell-stromal interactions [11] . Macrophages are generally classified into two subsets: classical M1macrophages with antitumor properties, and alternative M2 macrophages with tumor-supporting functions. Most TAMs have a pronounced M2 phenotype, which promotes tumor growth, metastasis, and angiogenesis [11] [12] [13] . Thus, elucidating the mechanisms by which TAMs sustain tumor growth and facilitate metastasis should help improve or design immuno-based strategies against cancer.
TRIM59, also known as mouse ring finger protein 1 (Mrf1), belongs to the evolutionarily conserved tripartite motif (TRIM) family of proteins [14] . Most TRIM members possess ubiquitin ligase activity and are involved in many critical processes, such as immunity, antiviral proliferation, transcriptional regulation, cell differentiation, and cancer [15, 16] . At present, the role of TRIM59 is still controversial. Several studies reported that TRIM59 is upregulated in various tumors, such as breast, gastric, colon, lung, and cervical cancer, contributing to tumor proliferation, metastasis, and angiogenesis [16] [17] [18] . A study indicated that TRIM59 may suppress RIG-I-like receptor-induced activation of interferon-regulatory factors (IRFs) and NF-κB via interaction with evolutionarily conserved signaling intermediate in Toll pathways (ECSIT), suggesting that TRIM59 may serve as a multifunctional regulator of innate immunity [19] .
Our previous work showed that TRIM59 may be an essential molecule underlying the cytotoxic effect of bacillus Calmette Guérin (BCG) -activated macrophages on MCA207 fibrosarcoma cells [20] . In preliminary experiments, we also observed that the supernatant of RAW264.7 cells overexpressing TRIM59 had a strong cytotoxic effect on mouse B16 melanoma cell lines, and this effect was attenuated by a TRIM59blockingantibody (data not shown). However, the mechanism(s) by which TRIM59 expression in macrophages, and especially in TAMs, influences tumor cell activity and survival remains unclear.
In this study, we generated conditional KO mice with myeloid-specific deletion of TRIM59 (TRIM59-CKO mice) and evaluated the effects of TRIM59 -/ --M2 macrophages on the metastatic behavior of melanoma B16-F0 and B16-F10 cells. B16-F0 is the parent cell line. B16-F10 was obtained by a ten-time selective procedure. B16-F10 cell has stronger migration and invasion ability than B16-F0 cell, and B16-F10 cell is also more capable of forming lung metastatic nodules than B16-F0 cell. To this end, mouse B16 melanoma cell lines were exposed to conditioned media (CM) from bone marrow-derived, TRIM59 -/mouse macrophages differentiated into the M2 phenotype, and migration/invasion assays were conducted in vitro. In addition, subcutaneous tumor growth and formation of lung metastases of melanoma cells were evaluated in TRIM59-CKO animals. Our results support and expand previous research suggesting that TRIM59 expression in macrophages critically modulates metastasis in tumor cells, and may be a valuable target for cancer immunotherapy.
RESULTS

Melanoma growth is enhanced in mice bearing TRIM59 -/macrophages
Preliminary experiments showed that CM from macrophages overexpressing TRIM59 had cytotoxic effects on B16-F0 cells (data not shown). To determine whether TRIM59 expression in macrophages influences melanoma growth and migration/invasion, we subcutaneously injected B16-F10 mouse melanoma cells into WT and myeloid-specific TRIM59-CKO mice. Mean tumor volume ( Figure 1A -1B) was significantly greater in TRIM59-CKO mice compared to WT mice. In addition, overall survival was significantly decreased in TRIM59-CKO mice ( Figure 1C ). Following tumor resection, TAMs phenotypes were studied by flow cytometry. A previous study classified TAMs into different subpopulations based on the expression of Ly6C and MHCII. Accordingly, Ly6C lo MHCII hi TAMs are M1-like macrophages, and Ly6C lo MHCII lo TAMs are M2-like macrophages [21, 22] . Using this categorization, we found that TAMs inTRIM59-CKO mice presented mainly the M2 phenotype ( Figure 1D-1E ).
TRIM59 -/--M2 macrophages promote melanoma cell proliferation, migration, and invasion in vitro
In light of the above in vivo results, we carried out in vitro experiments to investigate the effects of macrophage TRIM59 deficiency on melanoma cell growth, migration, and invasion. To this end, we induced the differentiation of bone marrow-derived macrophages (BMDMs) from WT and TRIM59-CKO mice into M2 macrophages. The M2 phenotype was verified through RT-PCR by high expression of the M2 markers Arg-1, IL-10, and Mrc1 and low expression of the M1 markers TNF-α, IL-6, and NOS2 (Figure 2A ). FACS analysis further showed that TRIM59 -/--M2 macrophages exhibited higher CD206 expression and lower MHCII expression than WT-M0 macrophages and WT-M2 macrophages. The expression of CD206 in WT-M2 macrophages was also higher than in nonpolarized (M0) WT macrophages ( Supplementary  Figure 2A ). We also performed immunofluorescence to detect F4/80 (macrophage marker) and CD206 (M2 phenotype macrophage marker), the results confirmed that M2 macrophages expressed high levels of CD206 ( Figure 2B ).
Next, melanoma B16-F0 and B16-F10 cells were incubated with CM from WT-M2 or TRIM59 -/--M2 macrophages. As shown in Figure 2C , although cell proliferation was promoted by either CM, the effect was significantly larger after incubation with CM from TRIM59 -/--M2 macrophages. Moreover, the latter also enhanced the migratory capability of B16-F0 and B16-F10 cells, measured through wound-healing assays, whereas WT-M2-CM had little effect ( Figure 2D ). Similarly, incubation with TRIM59 -/--M2 macrophage CM significantly increased invasion of B16-F0 and B16-F10cells through Matrigel-coated membranes in transwell assays, while WT-M2 macrophage CM had only a slight effect ( Figure 2E ).
Additional assays were conducted in human melanoma A375 cells pre-treated with CM from M2-polarized TRIM59 +/+ and TRIM59 -/human THP1 macrophages.
Results showed that CM from TRIM59 -/--THP1 cells enhanced migration and invasion of A375cells, whereas control THP1 CM had little effect (Supplementary Figure 1B-1C ). In addition, we detected the cytotoxic effects of the CM from THP1 which overexpressed TRIM59 on A375 cells. The results are THP1 conditioned medium has notably little cytotoxicity on A375 while CM from TRIM59 ovexpressed THP1 cells showed prominent cytotoxicity in killing A375 (Supplementary Figure 1D ). Overall, these results suggest that loss of TRIM59 is correlated with a protumoral function of M2 macrophages.
High TNF-α production by TRIM59 -/--M2 macrophages promotes MMP9 and Madcam1 expression in melanoma cells
To investigate the mechanism by which TRIM59 -/--M2 macrophage CM promoted the migration and invasion of melanoma cells, we used ELISA to detect the concentrations of relevant cytokines in M2 macrophage supernatants. We found a ~15-fold increase in tumor necrosis factor-α (TNF-α) contents in CM from M2 macrophages, relative to CM from non-differentiated (M0) cells. In turn, TNF-α levels in CM from TRIM59 -/--M2 macrophages were significantly higher than in CM from WT-M2 macrophages. At the same time, we observed that synthesis of pro-inflammatory factors such as IL-6 and IL-1β was increased in M2 macrophages, but there was no significant difference between TRIM59 -/--M2 CM and WT-M2 CM. IL-10 was also increased in M2 macrophages, while TGF-β was basically unchanged ( Figure 3A ). Next, we compared gene expression patterns between B16-F10 cells cultured with either TRIM59 -/--M2 macrophage CM. A total of 813 differentially expressed genes (DEGs), comprising 648 upregulated and 165 downregulated transcripts, were detected by transcriptome analysis ( Figure 3B ). These DEGs were classified according to gene ontology (GO) analysis ( Figure 3C ). 68 DEGs were associated with regulation of cell migration; these included genes encoding chemokines (ccl2, cxcl3, cxcl5, ccl20, and cxcl1), matrix metalloproteinases (MMPs), i.e. MMP-9 andMMP-12, and the adhesion molecule Madcam1 ( Figure 3D ). The transcriptome sequencing results were validated by quantitative RT-PCR. Compared with the control group, ccl2, MMP-12, MMP-9, and Madcam1 gene levels were significantly up-regulated in B16-F0 and B16-F10 cells cultured with CM from TRIM59 -/--M2 macrophages ( Figure 3E ).
To reconcile the above ELISA and gene expression data, we tested the effects of TNF-α on the expression of some key DEGs. Addition of recombinant mouse TNF-α (100 ng/ml) upregulated ccl2, MMP12, MMP9, and Madcam1 mRNA in both B16-F0 and B16-F10 cells ( Figure 3F ). Conversely, blockade of TNF-α synthesis in TRIM59 -/--M2 macrophage cultures using a neutralizing antibody significantly negated MMP-9 and Madcam1 induction in both B16-F0 and B16-F10 cells exposed to the corresponding CM ( Figure 3G ). Taken together, these results suggest that TNF-α production by TRIM59 -/--M2 macrophages promotes the expression of MMP-9 and Madcam1 in B16-F0 and B16-F10 tumor cells, enhancing their metastatic potential.
Conditioned media from TRIM59 -/--M2 macrophages activates the ERK pathway in melanoma cells
To further assess the molecular changes underpinning enhanced migration and invasion of B16-F0 and B16-F10 cells exposed to CM from M2-polarized macrophages, the activation status of the PI3K and the ERK signaling pathways was examined by western blotting. Compared with control media, CM from M2 macrophages induced pronounced increases in PI3K phosphorylation (Tyr458), Akt phosphorylation (Ser473), c-raf phosphorylation (Ser289), and ERK1/2 phosphorylation (Thr202/Tyr204) in both B16-F0 and B16-F10 cells. These changes were especially marked in melanoma cells exposed to CM from TRIM59 -/--M2macrophages, compared with CM from WT-M2 cells ( Figure 4A ). ERK signaling is an important regulator of cancer cell proliferation, migration, and invasion in many tumor types. We verified that ERK signaling is activated by TNF-α (100 ng/ml) in B16-F0 and B16-F10 cells, while antibody-mediated TNF-α inhibition significantly decreased this activation ( Figure 4B ). Furthermore, in both cell types inhibition of ERK1/2 with U0126 (10 μM) suppressed migration and invasion induced by CM from M2 macrophages (either WT orTRIM59 -/-; Figure 4C -4D), while the Akt inhibitor MK2206 (10 μM), tested in B16-F10 cells, was less effective (Supplementary Figure 3A-3C ). In turn, ERK signaling inhibition in B16-F0 and B16-F10 cells abolished the upregulation of MMP-9 and Madcam1 mRNA observed after stimulation with CM from M2 macrophages ( Figure 4E ). These data suggest that TRIM59 deficiency triggers TNF-α production by M2 macrophages, which promotes migration and invasion of melanoma cells mainly via activation of the ERK pathway and subsequent upregulation of MMP-9 and Madcam1.
MMP-9 and Madcam1 knockdown decreases migration and invasion and suppresses epithelialmesenchymal transition in melanoma cells
To verify the role of MMP-9 and Madcam1 in B16-F0 and B16-F10 cells, specific shRNAs were used to inhibit their expression. Transfection with MMP-9-shRNA decreased basal MMP-9 mRNA levels by ~3-and 3.5fold in B16-F0 and B16-F10 cells, respectively. In turn, Madcam1-shRNA transfection reduced basal Madcam1 mRNA levels by ~ 4-fold in both B16-F0 and B16-F10 cells ( Figure 5A ). Decreased MMP-9 and Madcam1 protein levels were confirmed by western blotting ( Figure 5B ). Knockdown of either MMP-9 or Madcam1 significantly decreased the migration of B16-F0 and B16-F10 cells in response to CM from TRIM59 -/--M2 macrophages ( Figure 5C ). Similar effects were observed on transwell invasion assays ( Figure 5D ).
Based on these findings, we used western blotting to test the hypothesis that MMP-9 and Madcam1 might regulate epithelial-mesenchymal transition (EMT) in B16 cells. Consistent with EMT repression, results showed that MMP-9 or Madcam1 knockdown up-regulated E-cadherin and downregulated N-cadherin, vimentin, β-catenin, snail, and CCDN1 in B16-F0 and B16-F10 cells.
MMP-9 and Madcam1 knockdown inhibits B16-F10 tumor progression and metastatic burden
To assess the effects of MMP-9 and Madcam1 deletion on tumor growth in vivo, we subcutaneously injected B16-F10 cells transfected with shRNA-MMP-9, shRNA-Madcam1, or scrambled control-shRNA into WT or TRIM59-CKO mice. B16-F10 control cells in TRIM59-CKO mice produced the largest tumors in WT with scrambled control-shRNA group, TRIM59-CKO with scrambled control-shRNA group, TRIM59-CKO with shRNA-MMP-9 group and TRIM59-CKO with shRNA-Madcam1 group, while those generated in the shRNA-MMP-9 and shRNA-Madcam1 groups were significantly smaller ( Figure 6A ). This was consistent with decreased proliferation, indicated by reduced Ki67 immunostaining, in tumors generated by sh-MMP-9and sh-Madcam1-transfected B16-F10cells ( Figure 6B ). Both immunohistochemistry and qRT-PCR confirmed decreased MMP-9 and Madcam1 expression in tumor samples derived from cells in which MMP9 or Madcam1 were knocked down ( Figure 6B-6C ).
To evaluate potential contributions of MMP-9 and Madcam1 to metastasis formation by melanoma cells, B16-F10 cells transfected with shRNA-MMP-9, shRNA-Madcam1, or scrambled control-shRNA were injected intravenously into WT or TRIM59-CKO mice. Although lung metastatic nodules developed in all mice, they were more numerous in TRIM59-CKO mice injected with control B16-F10 cells. In contrast, lung metastatic nodules were less numerous in the shRNA-MMP-9 and shRNA-Madcam1 groups (Figure 7) . These results indicated that MMP-9 or Madcam1 deletion attenuates lung metastatic colonization by melanoma cells facilitated by myeloid-specific TRIM59 knockdown.
DISCUSSION
This study shows that the growth of B16 melanoma allografts was stimulated by myeloid-specific TRIM59 knockdown in host mice, indicating that TRIM59 expression in TAMs may prevent or attenuate melanoma progression. Phenotypic analysis showed that the M2 phenotype prevailed among isolated TRIM59 -/ -TAMs. Exposure to TRIM59 -/--M2 macrophage supernatant promoted migration and invasion of B16 melanoma cells, and inhibitory experiments indicated that overexpression of TNF-α by TRIM59-deficient M2 macrophages and activation of ERK, and perhaps PI3K, signaling in B16 melanoma cells mediated these effects. RNA sequencing identified a large number of DEGs in B16-F10 cells exposed to TRIM59 -/--M2 macrophage CM. Among the top 15 DEGs, we selected MMP-9 and Madcam1, i.e. two genes involved in cell motility processes, and confirmed their regulation by TNF-αinduced ERK activation. Independent knockdown of either MMP-9 or Madcam1 by shRNA in melanoma cells inhibited EMT and invasion induced by TRIM59 -/--M2 macrophage CM, and attenuated the growth of subcutaneous B16-F10 tumors and reduced lung metastasis burden in TRIM59-CKO-mice.
Originally described as a circulating factor that can cause necrosis in tumors, TNF-α is now known to be a key regulator of inflammatory and immune responses [23] . TNF-α exerts multiple, context-dependent actions, and has been deemed a tumor-promoting factor for its ability to promote tumor survival by indirect mechanisms (e.g. immunosuppression) or direct effects on cancer cells (e.g. induction of EMT) [24] . Inflammation within the tumor microenvironment critically contributes to tumor development [25] . Accordingly, studies showed that upregulation of TNF-α in endothelial and immune cells promotes early tumor inflammation and stromal interactions that facilitate tumor invasion and metastasis [26] [27] [28] [29] [30] [31] . In some tumor types, TNF-α was shown to promote tumor cell migration and metastasis by inducing RAS or c-MYC activation and expression of MMPs (e.g. MMP-3 and 9) [32] [33] [34] [35] [36] . TNF-α can also stimulate the transcription of genes encoding endothelial cell adhesion molecules, including E selectin, ICAM-1, VCAM-1, and Madcam1, which are closely related to tumor metastasis and angiogenesis [37] [38] [39] . Our study showed that TNF-α promoted the expression of MMP-9 and Madcam1 in melanoma cells, which contributed to melanoma growth and metastasis. Because knockdown of MMP-9 did not alter Madcam1 protein levels, and Madcam1 silencing did not affect MMP-9 protein expression, we conclude that the effects were independent, and that both proteins are needed for metastatic dissemination of melanoma cells.
TRIM59, a member of the TRIM ubiquitin ligase family, has long been considered a tumor marker in association with tumor progression and metastasis in several tumor types, such as non-small cell lung cancer, gastric cancer, osteosarcoma, and cervical cancer [17, [43] [44] [45] [46] . A recent study reported that depletion of TRIM59 suppresses breast cancer metastasis by promoting RNFT1-induced K63 poly ubiquitination and SQSTM1-directed autophagic degradation of PDCD10 [40] . Another study reported that TRIM59 promotes gliomagenesis by inhibiting TC45 dephosphorylation of STAT3 [41] . TRIM59 can also regulate autophagy by modulating both the transcription and ubiquitination of BECN1 [42] . Interestingly, we found that TRIM59 expression is induced in BCG-stimulated macrophages and mediates a cytotoxic effect by direct cell contact on MCA207 fibrosarcoma cells [20] . In the present work, TRIM59 deficiency stimulated the metastatic potential of melanoma cells, suggesting that expression of TRIM59 in macrophages may have antitumor effects. We also found that TRIM59 expression in macrophages did not alter their phenotype, but significantly increased phagocytic activity [47] , which may be a mechanism involved in the antitumor response.
M2-like macrophages predominate in the tumor microenvironment, and play a stimulatory role on tumor development and metastasis [48, 49] . In our study, we found that deletion of TRIM59 further enhanced the tumor-promoting actions of M2 macrophages by inducing production and the release of TNF-α. Recent studies indicated the involvement of several ubiquitin ligases, including TRIM family members such as TRIM45, in the regulation of the MAPK signaling pathway (through alterations in AP-1/Elk-1transcriptional activity) and the NF-κB signaling pathways [50] [51] [52] . In our study, TRIM59 -/macrophages mediated upregulation of the PI3K and ERK signaling pathways in B16 melanoma cells, promoting MMP-9 and Madcam1 expression and stimulating migration and invasion in vitro, as well as tumorigenesis, EMT, and metastasis in an in vivo tumor model.
In conclusion, our study suggested that expression of TRIM59 in macrophages potentially restricts melanoma progression and metastasis, and its loss has pro-tumoral effects via induction of TNF-α. This evidence highlights that upregulation of TRIM59 in TAMs could be an effective way to attenuate or prevent tumor growth, in melanoma and perhaps other cancers. 
MATERIALS AND METHODS
Cell culture
B16-F0 and B16-F10 mouse melanoma cells, primary mouse bone marrow-derived macrophages, THP1 cells, and A375 human melanoma cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics. All cells were cultured in a humidified atmosphere of 5% CO2 at 37°C. 
Antibodies and reagents
Animals
All animal studies were conducted in accordance with the guidelines established by the Animal Research Committee of Jilin University. The TRIM59 targeting vector was constructed by flanking the exons of TRIM59 with 2 loxP sequences. TRIM59 Flox/Flox (TRIM59 F/F ) mice were produced by homologous recombination using the C57BL/6N ES cell line RENKA (Cyagen Biosciences Inc., Guangzhou, China). TRIM59 F/F mice were crossed with Lyz2-Cre transgenic mice (Jackson Laboratories, Bar Harbor, USA) to produce TRIM59 F/F : Lyz2-Cre (TRIM59-CKO) mice. These mice only knocked out TRIM59 in macrophages. These conventional macrophage TRIM59-KO mice were backcrossed onto the C57BL/6genetic background and used in the present study.
Tumor models
For subcutaneous tumor implantation, B16-F0 or B16-F10 melanoma cells transfected with control shRNA or shRNAs targeting either MMP-9 or Madcam1 were injected subcutaneously (5×10 5 cells in 150 μl saline) into the sides of 8-to 10-week-old female WT or TRIM59-CKO mice. Tumor volume (in mm 3 ) was measured twice a week with a digital caliper and calculated by the following formula: volume = (width) 2 × length/2. On day 28 post-implantation mice were sacrificed, and tumors were harvested for downstream experiments.
To evaluate metastasis development in vivo, B16-F0 or B16-F10 melanoma cells transfected with control shRNA, or shRNAs targeting either MMP-9 or Madcam1 were injected intravenously (5 × 10 5 cells in 100 μl saline) into 8-to 10-week-old female WT or TRIM59-CKO mice. For all animal experiments, at least five mice were randomly selected and included in each experimental group, and all animals used were included in the analysis.
Bone marrow-derived macrophage (BMDM) induction and conditioned medium preparation
Bone marrow cells were flushed from mouse bones and cultured in DMEM (20% FBS, 2 mM L-glutamine, 50 μM 2-mercaptoethanol) with 40 ng/ml macrophage colony stimulating factor (M-CSF). The medium was changed every two days, and the cells differentiated into BMDMs in one week. To generate M2 macrophages, BMDM cells were cultured with 25 ng/ml IL-4 and 25 ng/ml IL-13 for 48 h, and IL-4 and IL-13 were then removed by thorough washing. M2 cells were further cultured in 2 mL fresh serum-free DMEM for another 24 h to produce the conditioned media from M2 cells. Conditioned media was collected and stored at 80 °C.
Cell proliferation, wound healing and transwell assays
Cells were cultured in serum-free DMEM for 24 h before seeding at 1 × 10 3 cells per well in 96-well plates in control media, WT-M2 conditioned media, orTRIM59 -/--M2 conditioned media. Cell proliferation was measured using Cell Count Kit-8 (CCK-8) reagent (10 μl was added to each well at the endpoint) at the indicated times according to the manufacturer's instructions (Dojindo Laboratories, Kumamoto, Japan). In wound healing assays, melanoma cancer cells were seeded into 6-well plates and scraped using a sterile pipette tip. Images were obtained using an inverted microscope at 0 and 24 h and then analyzed by ImageJ software (NIH, Bethesda, MD, USA). For cell invasion assays, melanoma cancer cells were seeded into Matrigel-coated upper chambers of Transwell inserts (Corning, NY, USA). After 24 h of incubation, non-invading cells were scraped off with a cotton swab, and the cells on the bottom of the chamber were fixed, stained, and counted.
Flow cytometry and immunofluorescence
Flow cytometry and/or immunofluorescence was used to analyze F4/80, CD11b, MHCII, and Ly6C expression in TAM subtypes, and F4/80, MHCII, and CD206 expression in BMDM subtypes. APC/Cy7-Ly6C (557661), PE-F4/80 (565410), and FITC-CD11b (557396) were from BD Biosciences (San Jose, CA, USA); APC-MHCII (107614) and FITC-CD206 (141703) were from BioLegend (San Diego, CA, USA).
Enzyme-linked immunosorbent assay (ELISA)
Murine TNF-α, IL-6, IL-1b, IL-10, and TGF-β were measured in serum-free CM from WT-M0, WT-M2, TRIM59-CKO-M0, and TRIM59-CKO-M2 cells using murine ELISA kits purchased from eBioscience (San Diego, CA, USA) according to the manufacturer's instructions. Murine IL-2 was measured in serum free CM from WT-M0, WT-M2, and TRIM59-CKO-M2 cells using murine ELISA kits purchased from R&D Systems (Minneapolis, MN, USA). Absorbance was measured at 450 nm and corrected at 540 nm using a microplate reader. Total protein concentrations in CM were calculated using CurveExpert 1.4. (CurveExpert and GraphExpert Software, Madison, AL). Statistical analysis was performed using Student's t-test. A p < 0.05 was considered statistically significant.
Western blot analysis
Cells were harvested and lysed in lysis buffer (50mM Tris-HCl, 1% NP40, 150 mM NaCl, 1mM EDTA, and 1mM PMSF) for 30 min at 4°C. Total cell extracts were separated using 12% sodium dodecyl sulfatepolyacrylamide gels and transferred to polyvinylidene difluoride membranes. The membranes were blocked with 3% bovine serum albumin and incubated with primary antibodies diluted in blocking solution. Signals were visualized using a chemiluminescent substrate (Super Signal West Pico Kit; Thermo Scientific, IL, USA).
RNA isolation and quantitative real-time PCR
Total RNA was extracted from cultured or sorted macrophages using TRIzol reagent (Takara, Tokyo, Japan) according to the manufacturer's instructions. cDNA was synthesized and analyzed via quantitative real-time PCR with SYBR Mix. Expression levels of the target genes were normalized to that of the control gene.
Cell transfection
MMP-9 and Madcam1 shRNA plasmids and shRNA negative control were purified and synthesized by Gene-Pharma (Shanghai, China). Transfection was performed using polyethylenimine transfection reagent (Polysciences, Inc., Warrington, PA). RNA sequences were as follows: Sh-MMP-9: 5′-3′CCAACUAUGACCA GGAUAATT, 3′-5′UUAUCCUGGUCAUAGUUGGTT; Sh-Madcam1: 5′-3′GCUCUUGUUUGCCGAGCUATT, 3′-5′UAGCUCGGCAAACAAGAGCTT.
Immunohistochemistry
Tumors from WT or TRIM59-CKO mice were fixed for 72 h with 10% buffered formalin before paraffin embedding. Serial tissue sections (2 μm thick) were deparaffinized in xylene, rehydrated with a series of ethanol solutions (100% to 50%), and incubated in a 0.3% hydrogen peroxide solution for 20 min to block endogenous peroxidase activity. Sections were then rinsed with tap water, washed with phosphate-buffered saline (PBS) and subjected to antigen retrieval by boiling in a Tris/EDTA (pH 9.0) solution for 20 min. Subsequently, the sections were cooled, rinsed with tap water and PBS, and incubated with normal serum at room temperature for 30 min, followed by hematoxylin and eosin (H&E) staining or IHC. For IHC, the sections were incubated with MMP-9 or Madcam1 primary antibodies overnight at 4 °C. After rinsing with PBS three times, the slides were incubated for 30 min with HRP-conjugated secondary antibodies. Signal was developed using a 3′-diaminobenzidine (DAB) kit (Solarbio, Beijing, China).
Statistical analysis
Data were analyzed using unpaired Student's t test and are expressed as mean ± SD. P < 0.05 was considered statistically significant. All graphs and statistical calculations were performed using GraphPad Prism software (Version 6.0; La Jolla, CA, USA).
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